47.13

2.77% +1.27

After Hours: 47.13

Apogee Therapeutics Inc. (APGE)

Overview News Price History Discussions Forecast

Apogee Therapeutics Inc. stock is currently priced at $47.13, with a 24-hour trading volume of 237.23K. It has seen a +2.77% increased in the last 24 hours and a -28.30% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $45.40 pivot point. If it approaches the $47.19 resistance level, significant changes may occur.

Previous Close:

$45.86

Open:

$46.17

24h Volume:

237.23K

Market Cap:

$2.66B

Revenue:

Net Income/Loss:

$-71.91M

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+0.47%

1M Performance:

-28.30%

6M Performance:

+214.20%

1Y Performance:

+0.00%

1D Range:

$44.52

$47.47

52W Range:

$14.19

$72.29

Apogee Therapeutics Inc. Stock (APGE) Company Profile

Name

Apogee Therapeutics Inc.

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

650-394-5230

Address

221 Crescent Street, Building 17 Suite 102b, Waltham

Employee

Twitter

Next Earnings Date

Latest SEC Filings

APGE's Discussions on Twitter

Apogee Therapeutics Inc. Stock (APGE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-23	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	Guggenheim	Buy
Aug-08-23	Initiated	Jefferies	Buy
Aug-08-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Wedbush	Outperform

View All

Apogee Therapeutics Inc. Stock (APGE) Latest News

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Zacks Investment Research

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

GlobeNewswire Inc.

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Benzinga

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

GlobeNewswire Inc.

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

GlobeNewswire Inc.

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

GlobeNewswire Inc.

Apogee Therapeutics Inc. Stock (APGE) Financials Data

Apogee Therapeutics Inc. (APGE) Net Income 2024

APGE net income (TTM) was -$71.91 million for the quarter ending September 30, 2023.

Apogee Therapeutics Inc. (APGE) Earnings per Share 2024

APGE earnings per share (TTM) was -$10.83 for the quarter ending September 30, 2023.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.